The company resolved on March 13, 2026 to divest all shares of its subsidiary Wellness More Laboratories Co., Ltd., causing it to cease being a specified subsidiary. The divestiture follows a post-acquisition reassessment that revealed uncertainties in the subsidiary's growth prospects and limited synergies with the parent company's core operations.
—
›
Summary
The company resolved on March 13, 2026 to divest all shares of its subsidiary Wellness More Laboratories Co., Ltd., causing it to cease being a specified subsidiary. The divestiture follows a post-acquisition reassessment that revealed uncertainties in the subsidiary's growth prospects and limited synergies with the parent company's core operations.
The company has decided to divest all shares of its subsidiary Spiral Sense Inc., which will result in the subsidiary ceasing to be a specified subsidiary. The divestiture is scheduled for March 31, 2026, and is intended to optimize the company group's management resources and maximize enterprise value by allowing Spiral Sense to develop under new ownership.
—
›
Summary
The company has decided to divest all shares of its subsidiary Spiral Sense Inc., which will result in the subsidiary ceasing to be a specified subsidiary. The divestiture is scheduled for March 31, 2026, and is intended to optimize the company group's management resources and maximize enterprise value by allowing Spiral Sense to develop under new ownership.
The company recorded a 36 million yen special loss from early redemption of convertible bonds issued in April 2021, and an additional 25 million yen loan loss provision for loans to subsidiary Axel Medica Co., Ltd. The loan loss provision is eliminated in consolidated accounting and does not impact consolidated earnings.
¥61M
›
Summary
The company recorded a 36 million yen special loss from early redemption of convertible bonds issued in April 2021, and an additional 25 million yen loan loss provision for loans to subsidiary Axel Medica Co., Ltd. The loan loss provision is eliminated in consolidated accounting and does not impact consolidated earnings.
The company's board of directors resolved on January 22, 2026, to acquire all shares of Wellness More Laboratories Inc. by exercising share acquisition warrants attached to convertible bonds and purchasing 100 shares from existing shareholders, thereby making the company a wholly-owned subsidiary. This acquisition qualifies as a material subsidiary change requiring disclosure under the Financial Instruments and Exchange Act.
—
›
Summary
The company's board of directors resolved on January 22, 2026, to acquire all shares of Wellness More Laboratories Inc. by exercising share acquisition warrants attached to convertible bonds and purchasing 100 shares from existing shareholders, thereby making the company a wholly-owned subsidiary. This acquisition qualifies as a material subsidiary change requiring disclosure under the Financial Instruments and Exchange Act.
Counterparty: Wellness More Laboratories Inc. (ウェルネスモアラボラトリーズ株式会社)